The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

MDM2 SNP309 and melanoma risk among women.

Print

Sub-category:
Cancer Genetics

Category:
Tumor Biology and Human Genetics

Meeting:
2008 ASCO Annual Meeting

Abstract No:
11099

Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 11099)

Author(s):
E. Firoz, M. A. Warycha, R. L. Shapiro, R. S. Berman, H. Kamino, F. Darvishian, L. Rolnitzky, J. Goldberg, I. Osman, D. Polsky

Abstract:

Background: Melanoma incidence rates vary with respect to age and gender. While melanoma incidence is higher in women than in men prior to 50 years of age, this trend reverses after age 50. This suggests that estrogen may impact melanoma development in young women. A single nucleotide polymorphism in the MDM2 gene (SNP309), which is involved in estrogen signaling, has been shown in other cancers to correlate with age at tumor onset in premenopausal women. Analysis of MDM2 SNP309 in melanoma has not been previously reported. Methods: 286 melanoma patients (121 female, 165 male, 57.5 median age) prospectively enrolled in the NYU Interdisciplinary Melanoma Cooperative Group were studied. DNA was isolated from human blood leukocytes and analyzed for SNP309 status by PCR-RFLP. Associations between SNP309 genotypes, age at tumor onset, and clinicopathologic features of melanoma were analyzed using chi-square, Fisher's exact, Wilcoxon, and Kruskal Wallis tests. Results: The distribution of SNP309 genotypes was significantly different between women <50 years of age (n=39, GG: 33.3%) and women >50 years of age (n=82, GG: 15.9%) (p=0.035). Women with a GG genotype had 2.82 times the chance of being diagnosed at <50 years of age as compared to women with TG+TT genotypes (95% CI: 1.05,7.82). Women with a TT genotype had 2.57 times the chance of being diagnosed at >50 years of age as compared to women with GG+TG genotypes (95% CI: 1.01,6.84). Of women with primary melanoma (n=89), the age of onset was 13 years earlier among those with a GG genotype (median 46 years) as compared to TG+TT genotypes (median 59 years) (p=.185). There was no association between SNP309 and melanoma age of onset among men, or clinicopathologic features of melanoma among men or women. Conclusions: Our data suggest that premenopausal women with a GG genotype at MDM2 SNP309 may be at increased risk for the development of melanoma. Also, among postmenopausal women, the TT genotype may be a risk factor for melanoma.


Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

1. MDM2 SNP309 and melanoma risk among women.

Meeting: 2008 ASCO Annual Meeting
Presenter: Elnaz Firoz
Session: Tumor Biology and Human Genetics (General Poster Session)


  Other Abstracts in this Sub-Category:

    

1. Follow-up MRI screening of BRCA1/2 mutation carriers.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 11000   First Author: P. Shah
Category: Tumor Biology and Human Genetics - Cancer Genetics

    

2. WNK1 haplotypes and bevacizumab-induced hypertension.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 11003   First Author: M. K. Frey
Category: Tumor Biology and Human Genetics - Cancer Genetics

    

3. Identification of a new breast cacner risk locus in a genome-wide association study of Ashkenazi Jews.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 11005   First Author: B. Gold
Category: Tumor Biology and Human Genetics - Cancer Genetics

    

More...


  Abstracts by E. Firoz :

    

1. MDM2 SNP309 and melanoma risk among women.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 11099   First Author: E. Firoz
Category: Tumor Biology and Human Genetics - Cancer Genetics

    

More...


  Presentations by E. Firoz :

    

1. MDM2 SNP309 and melanoma risk among women.

Meeting: 2008 ASCO Annual Meeting
Presenter: Elnaz Firoz
Session: Tumor Biology and Human Genetics (General Poster Session)

    

More...


  Educational Book Manuscripts by E. Firoz :

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.